Understanding Lepromatous Leprosy
Main Article Content
Abstract
The bacterium Mycobacterium leprae is responsible for the development of lepromatous leprosy (LL), which is a severe form of leprosy. Skin lesions that are widespread, nerve damage in the periphery, and systemic involvement as a result of a poor immune response to the pathogen are the characteristics that define this condition. The purpose of this manuscript is to provide a comprehensive review of lepromatous leprosy, with a particular emphasis on its pathogenesis, clinical manifestations, diagnostic approaches, and treatment strategies. In this discussion, the immunological aspects of learning disability (LL) are highlighted, including the role of regulatory T cells and cytokine profiles. Additionally, the difficulties associated with managing this disease in areas where it is endemic are investigated. Through the process of synthesising the existing body of literature, the purpose of this review is to improve patient outcomes and to contribute to a better understanding of LL.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. World Health Organization. (2021). Global leprosy (Hansen disease) update, 2020: Time to step-up prevention initiatives. Weekly Epidemiological Record, 96(36), 417-440.
II. Scollard, D. M., Adams, L. B., Gillis, T. P., Krahenbuhl, J. L., Truman, R. W., & Williams, D. L. (2006). The continuing challenges of leprosy. Clinical Microbiology Reviews, 19(2), 338-381.
III. Modlin, R. L. (2010). The innate immune response in leprosy. Current Opinion in Immunology, 22(1), 48-54.
IV. Geluk, A., & Ottenhoff, T. H. (2016). HLA and leprosy in the pre and postgenomic eras. Human Immunology, 77(1), 37-43.
V. Saini, C., Ramesh, V., & Nath, I. (2013). Increased circulating regulatory T cells in leprosy patients with erythema nodosum leprosum reactions. PLoS Neglected Tropical Diseases, 7(1), e1983.
VI. Duthie, M. S., Gillis, T. P., & Reed, S. G. (2011). Advances and hurdles on the way toward a leprosy vaccine. Human Vaccines, 7(11), 1172-1183.
VII. Truman, R. W., & Krahenbuhl, J. L. (2001). Viable M. leprae as a research reagent. International Journal of Leprosy and Other Mycobacterial Diseases, 69(1), 1-12.
VIII. Lockwood, D. N., & Suneetha, S. (2005). Leprosy: Too complex a disease for a simple elimination paradigm. Bulletin of the World Health Organization, 83(3), 230-235.